Current Environment: Production

Medical Services

Programs & Services

Languages

  • English

Education

Graduate School

PhD

University of Texas Medical School at Houston/MD Anderson Cancer Center

1996, Houston, TX

Medical School

University of Texas Medical School at Houston

1997, Houston, TX

Residency

Anatomic Pathology

Brigham and Women's Hospital

1999, Boston, MA

Fellowship

Neuropathology

Brigham and Women's Hospital/Boston Children's Hospital

2001, Boston, MA

Certifications

  • American Board of Pathology (Anatomic)
  • American Board of Pathology (Neuropathology)

Publications

  1. Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nature. 2025 May 21. View Abstract

  2. High-throughput single-cell density measurements enable dynamic profiling of immune cell and drug response from patient samples. Nat Biomed Eng. 2025 May 20. View Abstract

  3. Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis. Neuro Oncol. 2025 May 15; 27(4):993-1003. View Abstract

  4. Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics. Nat Genet. 2025 May; 57(5):1168-1178. View Abstract

  5. The multilayered transcriptional architecture of glioblastoma ecosystems. Nat Genet. 2025 May; 57(5):1155-1167. View Abstract

  6. Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure. Cell Rep Med. 2025 May 20; 6(5):102095. View Abstract

  7. Investigative needle core biopsies support multimodal deep-data generation in glioblastoma. Nat Commun. 2025 Apr 28; 16(1):3957. View Abstract

  8. Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma. Clin Cancer Res. 2025 Mar 17; 31(6):983-992. View Abstract

  9. Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. Cancer Cell. 2025 Apr 14; 43(4):740-756.e8. View Abstract

  10. A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma. Sci Transl Med. 2025 Feb 19; 17(786):eadn6274. View Abstract

  11. Genomic Profiling Reveals SMARCA4 Mutations Are Associated with Shorter Overall and Intracranial Progression-Free Survival in Patients with Melanoma Brain Metastases. Clin Cancer Res. 2025 Feb 17; 31(4):719-732. View Abstract

  12. Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2025 Jan 17; 31(2):316-327. View Abstract

  13. Increased SOX10, p16, and Cyclin D1 Immunoreactivity Differentiates MAP Kinase-activated Low-grade Gliomas From Piloid Gliosis. Am J Surg Pathol. 2025 Apr 01; 49(4):347-352. View Abstract

  14. Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors. Neuro Oncol. 2025 Jan 12; 27(1):195-208. View Abstract

  15. Multimodal deep learning improves recurrence risk prediction in pediatric low-grade gliomas. Neuro Oncol. 2025 Jan 12; 27(1):277-290. View Abstract

  16. Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. Nat Commun. 2024 12 30; 15(1):10757. View Abstract

  17. Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 2024 Dec 09; 42(12):2124. View Abstract

  18. A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients. Neuro Oncol. 2024 Dec 05; 26(12):2364-2376. View Abstract

  19. Pilot Trial of Perampanel on Peritumoral Hyperexcitability in Newly Diagnosed High-grade Glioma. Clin Cancer Res. 2024 Dec 02; 30(23):5365-5373. View Abstract

  20. Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae202. View Abstract

  21. A pathology foundation model for cancer diagnosis and prognosis prediction. Nature. 2024 Oct; 634(8035):970-978. View Abstract

  22. GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant. Cancer Cell. 2024 Aug 27. View Abstract

  23. Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Aug 22; 15(1):7218. View Abstract

  24. Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma. medRxiv. 2024 Aug 14. View Abstract

  25. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837. View Abstract

  26. Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae115. View Abstract

  27. Noninvasive Molecular Subtyping of Pediatric Low-Grade Glioma with Self-Supervised Transfer Learning. Radiol Artif Intell. 2024 May; 6(3):e230333. View Abstract

  28. Measuring single-cell density with high throughput enables dynamic profiling of immune cell and drug response from patient samples. bioRxiv. 2024 Apr 28. View Abstract

  29. Pilot trial of perampanel on peritumoral hyperexcitability and clinical outcomes in newly diagnosed high-grade glioma. medRxiv. 2024 Apr 18. View Abstract

  30. A heterogeneous pharmaco-transcriptomic landscape induced by targeting a single oncogenic kinase. bioRxiv. 2024 Apr 10. View Abstract

  31. Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin. Commun Biol. 2024 04 08; 7(1):426. View Abstract

  32. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. Cancer Cell. 2024 May 13; 42(5):904-914.e9. View Abstract

  33. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma. Clin Cancer Res. 2024 Apr 01; 30(7):1327-1337. View Abstract

  34. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Neuro Oncol. 2024 03 04; 26(3):458-472. View Abstract

  35. Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping. Nat Med. 2024 Mar; 30(3):907. View Abstract

  36. Glioma genetic profiles associated with electrophysiologic hyperexcitability. Neuro Oncol. 2024 02 02; 26(2):323-334. View Abstract

  37. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. Mol Cell. 2024 Jan 18; 84(2):261-276.e18. View Abstract

  38. Investigative needle core biopsies for multi-omics in Glioblastoma. medRxiv. 2023 Dec 31. View Abstract

  39. Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. Neuro Oncol. 2023 12 08; 25(12):2165-2176. View Abstract

  40. Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning. medRxiv. 2023 Nov 22. View Abstract

  41. 2D and 3D multiplexed subcellular profiling of nuclear instability in human cancer. bioRxiv. 2023 Nov 11. View Abstract

  42. Liquid biopsy epigenomic profiling for cancer subtyping. Nat Med. 2023 Nov; 29(11):2737-2741. View Abstract

  43. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023 Nov; 623(7985):157-166. View Abstract

  44. Single-cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma. EMBO Mol Med. 2023 11 08; 15(11):e18144. View Abstract

  45. Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. J Clin Oncol. 2023 Dec 20; 41(36):5524-5535. View Abstract

  46. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas. Sci Transl Med. 2023 09 06; 15(712):eadi0069. View Abstract

  47. ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma. Clin Cancer Res. 2023 07 14; 29(14):2651-2667. View Abstract

  48. Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad083. View Abstract

  49. Machine learning for cryosection pathology predicts the 2021 WHO classification of glioma. Med. 2023 08 11; 4(8):526-540.e4. View Abstract

  50. Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume. Neuro Oncol. 2023 07 06; 25(7):1275-1285. View Abstract

  51. High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers. Nat Cancer. 2023 07; 4(7):1036-1052. View Abstract

  52. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers. Cancer Discov. 2023 06 02; 13(6):1478-1497. View Abstract

  53. Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma. Nat Commun. 2023 05 20; 14(1):2897. View Abstract

  54. Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma. Cell Mol Life Sci. 2023 May 12; 80(6):147. View Abstract

  55. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. bioRxiv. 2023 May 06. View Abstract

  56. Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation. Cells. 2023 03 21; 12(6). View Abstract

  57. Glioma genetic profiles associated with electrophysiologic hyperexcitability. medRxiv. 2023 Feb 24. View Abstract

  58. Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment. Sci Rep. 2023 02 21; 13(1):3051. View Abstract

  59. Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro Oncol. 2023 01 05; 25(1):199-210. View Abstract

  60. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023 01 05; 25(1):4-25. View Abstract

  61. Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdac182. View Abstract

  62. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Nat Genet. 2022 12; 54(12):1881-1894. View Abstract

  63. K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas. Nat Genet. 2022 12; 54(12):1865-1880. View Abstract

  64. BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma. Cancer Discov. 2022 12 02; 12(12):2880-2905. View Abstract

  65. Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma. Neuro Oncol. 2022 11 02; 24(11):2005-2007. View Abstract

  66. VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system. JCI Insight. 2022 10 10; 7(19). View Abstract

  67. PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors. Mod Pathol. 2022 12; 35(12):1770-1774. View Abstract

  68. FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits. Cancer Res. 2022 09 02; 82(17):2980-3001. View Abstract

  69. De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell. 2022 09 12; 40(9):939-956.e16. View Abstract

  70. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Nat Commun. 2022 08 16; 13(1):4814. View Abstract

  71. Generation of patient-derived models from a metastatic pediatric diffuse leptomeningeal glioneuronal tumor with KIAA1549::BRAF fusion. Acta Neuropathol. 2022 10; 144(4):793-797. View Abstract

  72. Correction to: Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma. J Neurooncol. 2022 Aug; 159(1):219. View Abstract

  73. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. Neuro Oncol. 2022 08 01; 24(8):1352-1363. View Abstract

  74. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nat Cancer. 2022 08; 3(8):994-1011. View Abstract

  75. Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro Oncol. 2022 07 01; 24(7):1140-1149. View Abstract

  76. Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma. J Neurooncol. 2022 Aug; 159(1):211-218. View Abstract

  77. A molecularly integrated grade for meningioma. Neuro Oncol. 2022 05 04; 24(5):796-808. View Abstract

  78. Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. J Neurooncol. 2022 May; 158(1):111-116. View Abstract

  79. Synthetic extracellular matrices and astrocytes provide a supportive microenvironment for the cultivation and investigation of primary pediatric gliomas. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac049. View Abstract

  80. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. J Neurooncol. 2022 May; 157(3):499-510. View Abstract

  81. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nat Commun. 2022 02 01; 13(1):604. View Abstract

  82. The Alliance AMBUSH Trial: Rationale and Design. Cancers (Basel). 2022 Jan 14; 14(2). View Abstract

  83. Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol. 2022 01 05; 24(1):64-77. View Abstract

  84. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 01 05; 24(1):101-113. View Abstract

  85. Mutational burden and immune recognition of gliomas. Curr Opin Oncol. 2021 11 01; 33(6):626-634. View Abstract

  86. Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. Cell Rep. 2021 10 05; 37(1):109788. View Abstract

  87. Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death. J Neuropathol Exp Neurol. 2021 11 19; 80(11):1052–1059. View Abstract

  88. Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2021 08 25; 37(16):2461-2463. View Abstract

  89. Rates and Patterns of Clonal Oncogenic Mutations in the Normal Human Brain. Cancer Discov. 2022 01; 12(1):172-185. View Abstract

  90. Prognostication for meningiomas: H3K27me3 to the rescue? Neuro Oncol. 2021 08 02; 23(8):1218-1219. View Abstract

  91. Effect of PIK3CA variants on glioma-related epilepsy and response to treatment. Epilepsy Res. 2021 09; 175:106681. View Abstract

  92. IDH-mutant gliomas with additional class-defining molecular events. Mod Pathol. 2021 07; 34(7):1236-1244. View Abstract

  93. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26. View Abstract

  94. Targeting glioblastoma using a novel peptide specific to a deglycosylated isoform of brevican. Adv Ther (Weinh). 2021 Apr; 4(4). View Abstract

  95. Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma. JAMA Oncol. 2020 12 01; 6(12):1972-1974. View Abstract

  96. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell. 2020 12 10; 183(6):1617-1633.e22. View Abstract

  97. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res. 2021 01 01; 27(1):276-287. View Abstract

  98. Loss of histone H3 trimethylation on lysine 27 and nuclear expression of transducin-like enhancer 1 in primary intracranial sarcoma, DICER1-mutant. Histopathology. 2021 Jan; 78(2):265-275. View Abstract

  99. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Mod Pathol. 2021 02; 34(2):264-279. View Abstract

  100. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Rep. 2020 09 29; 32(13):108196. View Abstract

  101. Epigenomic programming in early fetal brain development. Epigenomics. 2020 06; 12(12):1053-1070. View Abstract

  102. Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun. 2020 07 14; 8(1):107. View Abstract

  103. Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell. 2020 07 13; 38(1):44-59.e9. View Abstract

  104. Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Mol Cell. 2020 06 18; 78(6):1207-1223.e8. View Abstract

  105. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):716-724. View Abstract

  106. MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma. AJNR Am J Neuroradiol. 2020 05; 41(5):874-881. View Abstract

  107. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523. View Abstract

  108. WNT-Activated Medulloblastomas With Hybrid Molecular Subtypes. JCO Precis Oncol. 2020; 4. View Abstract

  109. Correction: BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene. 2020 Mar; 39(12):2641. View Abstract

  110. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet. 2020 02; 52(2):219-230. View Abstract

  111. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol. 2019 12 17; 21(12):1498-1508. View Abstract

  112. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol. 2020 02; 38(2):199-209. View Abstract

  113. BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene. 2020 03; 39(11):2305-2327. View Abstract

  114. Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers (Basel). 2019 Dec 12; 11(12). View Abstract

  115. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019 12; 576(7785):112-120. View Abstract

  116. Increasing value of autopsies in patients with brain tumors in the molecular era. J Neurooncol. 2019 Nov; 145(2):349-355. View Abstract

  117. Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathol. 2020 01; 139(1):193-209. View Abstract

  118. Pineal apoplexy due to pleomorphic variant pineocytoma. Clin Neuropathol. 2019 Sep/Oct; 38(5):253-255. View Abstract

  119. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 2019 10; 8(13):5988-5994. View Abstract

  120. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat Commun. 2019 08 19; 10(1):3731. View Abstract

  121. Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Res. 2019 10 01; 79(19):5088-5101. View Abstract

  122. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019 08 14; 11(505). View Abstract

  123. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 08 05; 21(8):968-980. View Abstract

  124. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. 2019 08; 572(7767):74-79. View Abstract

  125. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 08 08; 178(4):835-849.e21. View Abstract

  126. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400. View Abstract

  127. Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. Cureus. 2019 May 23; 11(5):e4726. View Abstract

  128. Recurrent EP300-BCOR Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features. J Neuropathol Exp Neurol. 2019 04 01; 78(4):305-314. View Abstract

  129. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3. View Abstract

  130. CHD4 regulates the DNA damage response and RAD51 expression in glioblastoma. Sci Rep. 2019 03 14; 9(1):4444. View Abstract

  131. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8. View Abstract

  132. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750. View Abstract

  133. The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. Nat Commun. 2019 01 25; 10(1):442. View Abstract

  134. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239. View Abstract

  135. miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. Oncogene. 2019 04; 38(16):2923-2936. View Abstract

  136. Linking single-cell measurements of mass, growth rate, and gene expression. Genome Biol. 2018 11 27; 19(1):207. View Abstract

  137. Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol. 2018; 2018. View Abstract

  138. Microfluidic active loading of single cells enables analysis of complex clinical specimens. Nat Commun. 2018 11 14; 9(1):4784. View Abstract

  139. The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have anti-proliferative effects. Neuro Oncol. 2018 11 12; 20(12):1594-1605. View Abstract

  140. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018 10 09; 20(11):1547-1555. View Abstract

  141. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell. 2018 09 20; 175(1):101-116.e25. View Abstract

  142. Correction to: DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathol. 2018 09; 136(3):505. View Abstract

  143. Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma. Neurology. 2018 09 11; 91(11):523-525. View Abstract

  144. A PDGFRa-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nat Commun. 2018 08 06; 9(1):3116. View Abstract

  145. The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro Oncol. 2018 08 02; 20(9):1162-1172. View Abstract

  146. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250. View Abstract

  147. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunol Res. 2018 09; 6(9):1039-1045. View Abstract

  148. Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Res. 2018 07 15; 78(14):4007-4021. View Abstract

  149. DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathol. 2018 08; 136(2):255-271. View Abstract

  150. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335. View Abstract

  151. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018 04 09; 20(5):674-686. View Abstract

  152. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol. 2018 03 27; 20(4):546-556. View Abstract

  153. Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. J Neurooncol. 2018 Apr; 137(2):269-278. View Abstract

  154. Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging. Clin Cancer Res. 2018 03 01; 24(5):1073-1081. View Abstract

  155. A novel GIT2-BRAF fusion in pilocytic astrocytoma. Diagn Pathol. 2017 Nov 15; 12(1):82. View Abstract

  156. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 01 15; 24(2):295-305. View Abstract

  157. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. J Neurooncol. 2017 Dec; 135(3):581-591. View Abstract

  158. Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. Am J Surg Pathol. 2017 Oct; 41(10):1410-1421. View Abstract

  159. Brainstem angiocentric gliomas with MYB-QKI rearrangements. Acta Neuropathol. 2017 Oct; 134(4):667-669. View Abstract

  160. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. J Clin Oncol. 2017 Sep 01; 35(25):2934-2941. View Abstract

  161. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol. 2017 Jul 01; 28(7):1457-1472. View Abstract

  162. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996. View Abstract

  163. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):908-917. View Abstract

  164. Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology. 2017 07 01; 158(7):2284-2291. View Abstract

  165. Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-ß Pathway. Cell Rep. 2017 06 13; 19(11):2410-2412. View Abstract

  166. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol. 2017 06 01; 19(6):750-761. View Abstract

  167. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017 06 01; 19(6):774-785. View Abstract

  168. Intracranial myxoid mesenchymal tumors with EWSR1-CREB family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity? Brain Pathol. 2018 03; 28(2):183-191. View Abstract

  169. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545. View Abstract

  170. A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Rep. 2017 03 28; 18(13):3167-3177. View Abstract

  171. Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. J Pathol. 2017 05; 242(1):24-38. View Abstract

  172. G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. Nat Cell Biol. 2017 03; 19(3):177-188. View Abstract

  173. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. Neuro Oncol. 2017 02 01; 19(2):219-228. View Abstract

  174. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol. 2016 Nov; 34(11):1161-1167. View Abstract

  175. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30. View Abstract

  176. Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-ß Pathway. Cell Rep. 2016 07 26; 16(4):950-966. View Abstract

  177. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 01; 19(1):109-117. View Abstract

  178. Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism". N Engl J Med. 2016 Jul 14; 375(2):196-8. View Abstract

  179. Genomic characterization of recurrent high-grade astroblastoma. Cancer Genet. 2016 Jul-Aug; 209(7-8):321-30. View Abstract

  180. MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063. View Abstract

  181. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 07; 22(7):723-6. View Abstract

  182. Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nat Neurosci. 2016 06; 19(6):798-806. View Abstract

  183. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun. 2016 Apr 06; 7:11185. View Abstract

  184. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol. 2016 06; 128(2):293-302. View Abstract

  185. Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. J Pathol. 2016 Mar; 238(4):584-97. View Abstract

  186. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016 Mar; 48(3):273-82. View Abstract

  187. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55. View Abstract

  188. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagn Pathol. 2016 Jan 27; 11:13. View Abstract

  189. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016 Jan; 126(1):165-174. View Abstract

  190. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016 Feb 18; 127(7):869-81. View Abstract

  191. A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies. J Vis Exp. 2015 Nov 07; (105):e53304. View Abstract

  192. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35. View Abstract

  193. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res. 2016 Mar 01; 22(5):1185-96. View Abstract

  194. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr; 18(4):557-64. View Abstract

  195. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177. View Abstract

  196. Somatic mutations associated with MRI-derived volumetric features in glioblastoma. Neuroradiology. 2015 Dec; 57(12):1227-37. View Abstract

  197. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74. View Abstract

  198. Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7. View Abstract

  199. Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. World Neurosurg. 2016 Jan; 85:96-105. View Abstract

  200. One size should not fit all: advancing toward personalized glioblastoma therapy. Discov Med. 2015 Jun; 19(107):471-7. View Abstract

  201. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63. View Abstract

  202. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8. View Abstract

  203. Calibrating genomic and allelic coverage bias in single-cell sequencing. Nat Commun. 2015 Apr 16; 6:6822. View Abstract

  204. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature. 2015 Apr 16; 520(7547):363-7. View Abstract

  205. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9. View Abstract

  206. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96. View Abstract

  207. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16. View Abstract

  208. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55. View Abstract

  209. Intermediate DNA methylation is a conserved signature of genome regulation. Nat Commun. 2015 Feb 18; 6:6363. View Abstract

  210. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015 Mar 20; 33(9):1015-22. View Abstract

  211. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Oncotarget. 2015 Jan 20; 6(2):1190-201. View Abstract

  212. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7. View Abstract

  213. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6. View Abstract

  214. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol. 2015 Sep; 17(9):1261-9. View Abstract

  215. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res. 2015 Feb 01; 21(3):585-93. View Abstract

  216. Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget. 2014 Nov 15; 5(21):10596-606. View Abstract

  217. Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models. Br J Cancer. 2014 Dec 09; 111(12):2275-86. View Abstract

  218. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro Oncol. 2015 May; 17(5):697-707. View Abstract

  219. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302. View Abstract

  220. Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii1-6. View Abstract

  221. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92. View Abstract

  222. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol. 2014 Nov; 128(5):733-41. View Abstract

  223. Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas. PLoS One. 2014; 9(9):e106694. View Abstract

  224. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8. View Abstract

  225. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan; 17(1):116-21. View Abstract

  226. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov; 16(11):1541-6. View Abstract

  227. Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii11-iii12. View Abstract

  228. Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47. View Abstract

  229. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11121-6. View Abstract

  230. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014 Aug; 4(8):956-71. View Abstract

  231. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014 May; 46(5):462-6. View Abstract

  232. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis. 2014 Mar 27; 5:e1145. View Abstract

  233. Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. Epilepsy Res. 2014 Jul; 108(5):843-52. View Abstract

  234. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest. 2014 Apr; 124(4):1636-45. View Abstract

  235. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev. 2014 Mar 01; 28(5):479-90. View Abstract

  236. Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta. 2014 Apr; 1845(2):294-307. View Abstract

  237. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr; 16(4):567-78. View Abstract

  238. ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep. 2014 Jan 30; 6(2):313-24. View Abstract

  239. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 Feb; 46(2):161-5. View Abstract

  240. Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy. Stem Cells. 2014 Jan; 32(1):313-26. View Abstract

  241. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013 Nov; 14(12):1200-7. View Abstract

  242. Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids. 2013 Oct 01; 2:e126. View Abstract

  243. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013 Nov; 19(11):1518-23. View Abstract

  244. Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. Sci Transl Med. 2013 Sep 04; 5(201):201ra119. View Abstract

  245. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013 Aug; 45(8):927-32. View Abstract

  246. Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&M algorithm. Genome Res. 2013 Sep; 23(9):1522-40. View Abstract

  247. Estimating absolute methylation levels at single-CpG resolution from methylation enrichment and restriction enzyme sequencing methods. Genome Res. 2013 Sep; 23(9):1541-53. View Abstract

  248. DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nat Genet. 2013 Jul; 45(7):836-41. View Abstract

  249. Enhancing radiation therapy for patients with glioblastoma. Expert Rev Anticancer Ther. 2013 May; 13(5):569-81. View Abstract

  250. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93. View Abstract

  251. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5. View Abstract

  252. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol. 2013 Sep; 23(5):565-73. View Abstract

  253. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9. View Abstract

  254. Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc Natl Acad Sci U S A. 2013 Jan 29; 110(5):1611-6. View Abstract

  255. Somatic mutations of PIK3R1 promote gliomagenesis. PLoS One. 2012; 7(11):e49466. View Abstract

  256. Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro Oncol. 2012 Nov; 14(11):1325-31. View Abstract

  257. Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer. 2012 Dec 15; 59(7):1155-7. View Abstract

  258. Brain and testicular tumors in mice with progenitor cells lacking BAX and BAK. Oncogene. 2013 Aug 29; 32(35):4078-85. View Abstract

  259. BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol. 2012 Sep; 71(9):789-94. View Abstract

  260. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98. View Abstract

  261. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Dis Model Mech. 2012 Nov; 5(6):881-94. View Abstract

  262. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881. View Abstract

  263. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012 Jun; 14(6):761-7. View Abstract

  264. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 Jul; 14(7):819-29. View Abstract

  265. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012 Apr 15; 26(8):756-84. View Abstract

  266. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron. 2012 Apr 12; 74(1):41-8. View Abstract

  267. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012 Feb 15; 483(7390):484-8. View Abstract

  268. Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget. 2012 Jan; 3(1):98-106. View Abstract

  269. Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Res. 2012 Feb 01; 72(3):645-54. View Abstract

  270. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn. 2011 Nov; 13(6):669-77. View Abstract

  271. Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):20388-93. View Abstract

  272. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun; 13(6):649-59. View Abstract

  273. Human glioma growth is controlled by microRNA-10b. Cancer Res. 2011 May 15; 71(10):3563-72. View Abstract

  274. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29; 6(3):e17948. View Abstract

  275. Glioma models: new GEMMs add "class" with genomic and expression correlations. Cancer Cell. 2011 Mar 08; 19(3):295-7. View Abstract

  276. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell. 2011 Mar 08; 19(3):359-71. View Abstract

  277. Development of stereotactic mass spectrometry for brain tumor surgery. Neurosurgery. 2011 Feb; 68(2):280-89; discussion 290. View Abstract

  278. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10; 29(11):1424-30. View Abstract

  279. Discrimination of human astrocytoma subtypes by lipid analysis using desorption electrospray ionization imaging mass spectrometry. Angew Chem Int Ed Engl. 2010 Aug 09; 49(34):5953-6. View Abstract

  280. Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. Am J Transl Res. 2010 May 16; 2(3):309-15. View Abstract

  281. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2010 Sep 01; 78(1):85-90. View Abstract

  282. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A. 2010 Feb 09; 107(6):2616-21. View Abstract

  283. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009 Dec; 11(6):853-60. View Abstract

  284. CRX is a diagnostic marker of retinal and pineal lineage tumors. PLoS One. 2009 Nov 20; 4(11):e7932. View Abstract

  285. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887. View Abstract

  286. FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell. 2009 Nov 06; 5(5):540-53. View Abstract

  287. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res. 2009 Oct 15; 15(20):6430-7. View Abstract

  288. Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. Cell. 2009 Jul 10; 138(1):172-85. View Abstract

  289. Array-based genomics in glioma research. Brain Pathol. 2010 Jan; 20(1):28-38. View Abstract

  290. Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb Symp Quant Biol. 2008; 73:427-37. View Abstract

  291. A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature. Pediatr Neurosurg. 2008; 44(6):501-8. View Abstract

  292. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 01; 15(1):330-7. View Abstract

  293. Meningioangiomatosis associated with meningioma: a case report. Acta Cytol. 2009 Jan-Feb; 53(1):93-7. View Abstract

  294. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008 Oct 23; 455(7216):1129-33. View Abstract

  295. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell. 2008 Aug 12; 14(2):123-34. View Abstract

  296. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008 Jun; 10(3):300-8. View Abstract

  297. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 2008 Apr; 13(4):355-64. View Abstract

  298. Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia. Brain Pathol. 2008 Apr; 18(2):153-63. View Abstract

  299. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007 Nov 01; 21(21):2683-710. View Abstract

  300. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol. 2007 Nov; 62(5):515-20. View Abstract

  301. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007 Oct 12; 318(5848):287-90. View Abstract

  302. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol. 2007 Jun; 31(6):836-45. View Abstract

  303. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues. Cancer Res. 2007 May 15; 67(10):4732-41. View Abstract

  304. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 2007 Feb 15; 53(4):503-17. View Abstract

  305. Disruption of diacylglycerol kinase delta (DGKD) associated with seizures in humans and mice. Am J Hum Genet. 2007 Apr; 80(4):792-9. View Abstract

  306. Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution. J Mol Diagn. 2007 Feb; 9(1):20-9. View Abstract

  307. Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol. 2006 Dec; 30(12):1613-8. View Abstract

  308. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol. 2006 Dec; 65(12):1149-56. View Abstract

  309. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006 Dec 01; 66(23):11502-13. View Abstract

  310. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res. 2006 Oct 15; 66(20):10171-8. View Abstract

  311. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature. 2006 Sep 28; 443(7110):453-7. View Abstract

  312. Olig gene function in CNS development and disease. Glia. 2006 Jul; 54(1):1-10. View Abstract

  313. Development of NG2 neural progenitor cells requires Olig gene function. Proc Natl Acad Sci U S A. 2006 May 16; 103(20):7853-8. View Abstract

  314. Evidence for motoneuron lineage-specific regulation of Olig2 in the vertebrate neural tube. Dev Biol. 2006 Apr 01; 292(1):152-64. View Abstract

  315. Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol. 2005 Nov; 64(11):948-55. View Abstract

  316. Diffusion-weighted imaging of fungal cerebral infection. AJNR Am J Neuroradiol. 2005 May; 26(5):1115-21. View Abstract

  317. Molecular diversity of astrocytes with implications for neurological disorders. Proc Natl Acad Sci U S A. 2004 Jun 01; 101(22):8384-9. View Abstract

  318. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol. 2004 May; 63(5):499-509. View Abstract

  319. Loss of Emx2 function leads to ectopic expression of Wnt1 in the developing telencephalon and cortical dysplasia. Development. 2003 May; 130(10):2275-87. View Abstract

  320. Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema. J Pediatr. 2003 Mar; 142(3):349-52. View Abstract

  321. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 2002 Apr; 1(3):269-77. View Abstract

  322. Cooperative transcriptional activation by the neurogenic basic helix-loop-helix protein MASH1 and members of the myocyte enhancer factor-2 (MEF2) family. J Biol Chem. 1996 Oct 25; 271(43):26659-63. View Abstract

  323. Paraxis: a basic helix-loop-helix protein expressed in paraxial mesoderm and developing somites. Dev Biol. 1995 Apr; 168(2):296-306. View Abstract

  324. Scleraxis: a basic helix-loop-helix protein that prefigures skeletal formation during mouse embryogenesis. Development. 1995 Apr; 121(4):1099-110. View Abstract

  325. Smooth muscle myosin heavy chain exclusively marks the smooth muscle lineage during mouse embryogenesis. Circ Res. 1994 Nov; 75(5):803-12. View Abstract

  326. Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. J Neurooncol. 1993 May; 16(2):125-33. View Abstract
BESbswy